Podcasts about tumors

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

Guest: Shiraz Baboo – Reality Addiction Expert, Author of How to Rewrite Reality, and Founder of Energetic Magic Episode Focus: How unconscious stories shape our physical reality, from chronic illness to financial blocks, and the radical process of rewriting them for lasting transformation. All Episodes can be found at ⁠⁠⁠⁠https://www.podpage.com/speaking-podcast/⁠⁠⁠   All about Roy / Brain Gym & Virtual Assistants at ⁠⁠⁠⁠https://roycoughlan.com/⁠⁠⁠⁠   #shiraz #ShirazBaboo #bodybuilder    Bio of Shiraz BabooMulti-award-winning author. Reality Interventionist. Creator of the Million Dollar Impact Makers Program.  I have helped thousands of coaches, healers, and high-achieving entrepreneurs break their subconscious addiction to struggle and rewrite the stories keeping them stuck—so they can finally grow their businesses in alignment with who they truly are. At Business Magic Live, I work with you live to release the unconscious patterns that are sabotaging your success… and replace them with the belief, clarity, and aligned action required to build a business that creates real wealth and lasting legacy.Most of the people who come to me already know the strategies. What's been missing isn't knowledge. It's the internal permission to execute, receive, and lead at the level those strategies require.   What we Discussed:   00:00 Introduction   01:00 Shiraz's Origin Story: From Bodybuilder to Bedridden   04:40 We are protecting ourselves through Stories   05:40 How I healed my Back Pain   06:30 Fake knee operations gave the same results   07:06 A woman with a Tumor that kept disappearing 08:00 Lessons learnt from living in different countries   11:50 How he kept getting Stopped at Border Control   18:00 How to navigate peoples issues without them knowing what is wrong   21:00 How he resolved his own Financial issues   23:00 My own Financial Struggles 23:20 Reviewing Why I have these Fears   25:50 If I had Money would it Corrupt me  29:05 Push & Pull Energy   32:00 Are you will to step out of the story   33:45 Reflecting on how I got seriouly injured every time I was relaxed   35:20 Do I always have to be on guard   37:00 You Do not have to worry about something to solve it   39:00 Common Patterns with clients   40:35 His Event Business Magic Live   42:00 People having a yo-yo with Finances   43:00 Where to find Shiraz and the Event   How to Contact Shiraz Baboo ⁠https://energeticmagic.com/⁠   ⁠https://www.facebook.com/energeticmagic/⁠   ⁠https://www.linkedin.com/in/shirazbaboo/⁠   ⁠https://www.youtube.com/energeticmagic⁠   ⁠https://www.instagram.com/energetic.magic/⁠   All about Roy / Brain Gym & Virtual Assistants at ⁠⁠⁠⁠https://roycoughlan.com/⁠⁠⁠⁠  

«Die violett eingefärbten Punkte meiner Krebszellen wirkten auf mich fast schön.» Nach ihrer Brustkrebsdiagnose wollte Frau Z. mehr wissen. Sie bat ihre Ärztin, die pathologischen Bilder ihres Tumors sehen zu dürfen und vor allem, sie erklärt zu bekommen. «Den Patientinnen und Patienten damit Sicherheit und Vertrauen zu geben, ist unser Ziel», erklären die Forschenden eines von der Krebsforschung Schweiz unterstützten Projektes. Die Idee dazu stammt vom Pathologen Gieri Cathomas (Institut für Gewebsmedizin und Pathologie, Universität Bern) und wurde gemeinsam mit der Psychoonkologin Marie-Louise Fontana sowie dem Psychoonkologen Alexander Wünsch weiterentwickelt. In interdisziplinären Sprechstunden erklären Fachpersonen den Befund und beantworten Fragen. Frau Z. geht es heute gut. Sie habe dank der Antworten des Pathologen ein besseres Verständnis von Brustkrebs und der Therapien, die sie durchgemacht hat.

El exitoso tratamiento prenatal para atacar el tumor que se alojaba en el cuello del bebé representa una primicia mundial para este tipo de afecciones. Conoce los detalles de esta y otras noticias positivas de la semana.

A atriz Sofia Alves é a convidada de Daniel Oliveira no Alta Definição. Aos 52 anos, revisita momentos marcantes da vida e da carreira, entre provações duras e uma fé que considera inabalável. Sofia recorda o susto de ter enfrentado um tumor, a urgência da cirurgia e o longo período de incerteza, bem como o impacto emocional que isso teve na família. Revela também o episódio traumático da zona que quase lhe tirou a visão e a complexa recuperação que obrigou a equipa da novela a recorrer a efeitos especiais para a manter em cena. “Tenho plena noção do que é a vida. Num momento estamos, no outro… deixamos de estar”, confessa. Na conversa, fala ainda da menopausa precoce, da perda de amigos próximos e da forma como o silêncio, a natureza e a oração lhe servem de refúgio. Partilha a relação profunda com o marido, Celso, a alegria que encontra no neto e a ligação especial a Margarida, a jovem atriz com trissomia 21 com quem contracena e a quem chama “filha do coração”. “Sou muito grata. A vida ensinou-me a não desistir”, afirma. Ouça o Alta Definição, em podcast, emitido na SIC em 21 de fevereiro 2026.* A sinopse deste episódio foi criada com o apoio de IA. Saiba mais sobre a aplicação de Inteligência Artificial nas Redações da Impresa See omnystudio.com/listener for privacy information.

Are we finished ruining soda for you? NOPE! Never.

This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management, Guests: Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom. Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy

Bone tumor treatment: when do you burn it and when do you freeze it? In this BackTable MSK Brief, Dr. Damian Dupuy joins Host Dr. Kavi Krishnasamy to discuss the technical nuances of radiofrequency ablation (RFA) and cryoablation, patient selection criteria, procedural strategies, and the importance of setting appropriate patient expectations. Dr. Dupuy also shares insights on preventing complications like cryomyositis and myoglobinuria, underscoring the balance between aggressive treatment and patient safety. Episode Outline 00:00 - Introduction 00:40 - Bone Tumor Interface and Time Under Treatment 05:10 - Patient Selection and Treatment Considerations 07:57 - Approach to Large Bony Lesions 12:37 - Best Treatment Modality: Cryoablation vs. RFA 13:38 - Managing Collateral Damage 15:58 - Navigating Patient Expectations Resources Dr. Damian E. Dupuy, MD, FACR https://www.linkedin.com/in/damian-e-dupuy-md-facr-6b080b1b/  Solitary painful osseous metastases: correlation of imaging features with pain palliation after radiofrequency ablation--a multicenter american college of radiology imaging network study https://pubmed.ncbi.nlm.nih.gov/23657892/

What could replace chemotherapy?In this episode of Beyond the Rounds, we explore cellular therapy, CAR-T cell therapy, tumor-infiltrating lymphocytes (TIL), and how modern immunotherapy is reshaping cancer treatment. Dr. Nolan Fisher sits down with hematologist and cellular therapy specialist Dr. Yazan Samhouri of Banner MD Anderson Cancer Center to break down how immune-based cancer treatments differ from traditional chemotherapy — and why the “last resort” label for CAR-T is quickly becoming outdated.This episode is designed for physicians, advanced practice providers, and clinicians who want a practical understanding of where cellular therapies fit in today's oncology landscape.What We Cover:• The difference between chemotherapy, immunotherapy, and cellular therapy• How CAR-T cell therapy works (Chimeric Antigen Receptor T-cells explained)• Tumor-infiltrating lymphocyte (TIL) therapy for solid tumors• Stem cell transplant vs. CAR-T — complementary or competing?• Cytokine release syndrome (CRS) and neurologic toxicity• Patient selection and referral timing• Why earlier referral matters in relapsed/refractory disease• Next-generation CAR-T and multi-antigen targeting• Off-the-shelf cellular therapies and the future of accessKey Topics for Clinicians:Hematologic malignanciesLymphoma and leukemiaMetastatic melanomaRelapsed/refractory cancerBridging therapy during CAR-T manufacturingFDA-approved immunotherapiesCancer clinical trialsMultidisciplinary cancer careAbout Our GuestDr. Yazan Samhouri is a specialist in hematology and cellular therapy at Banner MD Anderson Cancer Center. His clinical focus includes CAR-T therapy, stem cell transplantation, and advanced immunotherapeutic approaches for blood cancers and select solid tumors.DisclaimerThis podcast is intended for educational purposes only and is designed for a clinical audience. Any patient scenarios discussed are modified and de-identified to protect privacy. No protected health information (PHI) is disclosed. The information presented should not replace independent medical judgment or individualized patient care decisions.Subscribe to Beyond the Rounds for physician-focused conversations on clinical innovation, specialty collaboration, and evolving standards of care.

Los profesores de la UCLM Ricardo Sánchez-Prieto y María José Ruiz-Hidalgo son los responsables científicos de este estudio realizado por Jaime Jiménez y Francisco Cimas, que ha revelado cómo dos proteínas son clave en el desarrollo y progresión de los sarcomas regulando su proliferación y supervivencia.

Port wine birthmark treatment -PTEN hamartoma tumor syndrome -Nanobubble technology for ichthyosis -Reactive granulomatosis dermatitis in kids -Cardiac issues in X-linked ichthyosis -Timolol for chronic wounds - Check out Luke's Urticaria CMEexperience! aaaaicsu.gathered.com/invite/KQe1wPZbJY Learnmore about the U of U Dermatology ECHOmodel! physicians.utah.edu/echo/dermatology-primarycare Want to donate to the cause? Do so here!Donate to the podcast: ⁠uofuhealth.org/dermasphere⁠Check out our video content on YouTube:www.youtube.com/@dermaspherepodcast⁠and VuMedi!: ⁠www.vumedi.com/channel/dermasphere/⁠The University of Utah's DermatologyECHO: ⁠⁠physicians.utah.edu/echo/dermatology-primarycare⁠ -Connect with us!- Web: ⁠⁠dermaspherepodcast.com/⁠⁠ - Twitter: @⁠DermaspherePC⁠- Instagram: dermaspherepodcast- Facebook: ⁠www.facebook.com/DermaspherePodcast/⁠- Check out Luke and Michelle's other podcast,SkinCast! ⁠⁠healthcare.utah.edu/dermatology/skincast/⁠⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠⁠www.levelex.com/games/top-derm⁠⁠ (A free dermatology game to learn more dermatology!

Cancer care is rapidly shifting toward precision medicine—treatment guided by a tumor's biology and biomarkers rather than where it starts in the body. HER2 is a protein on some cancer cells that can drive tumor growth. In this episode, we explore what it means for HER2 to be a target across multiple solid tumors, how […]

Cancer care is rapidly shifting toward precision medicine—treatment guided by a tumor's biology and biomarkers rather than where it starts in the body. HER2 is a protein on some cancer cells that can drive tumor growth. In this episode, we explore what it means for HER2 to be a target across multiple solid tumors, how […]

Wenn keine Chemotherapie mehr anschlägt, hilft manchmal eine individuelle Gentherapie. Wie funktioniert das - und für wen?Zwölf Mal hat der Krebspatient Torben Lorenz Chemotherapie bekommen, doch der Tumor wuchs weiter. Dann brachte eine CAR-T-Zell-Therapie die Wende – ein innovatives Verfahren, bei dem Immunzellen des Patienten gentechnisch zur spezialisierten Eingreiftruppe umprogrammiert werden.Die Personalisierte Medizin gilt als Gamechanger in der Onkologie und in weiteren Bereichen der Medizin. Unsere Autorin Daniela Remus hat Torben Lorenz in Heide besucht und Genforscher, Neurologen und Onkologen zu den Perspektiven von CAR-T-Zellen, Checkpoint-Inhibitoren und therapeutischer mRNA-Impfung befragt. Im Gespräch mit Host Korinna Hennig erklärt sie, wie man Krebszellen daran hindern kann, das Immunsystem auszutricksen. Sie berichtet über große Chancen, aber auch ökonomische Grenzen der Personalisierten Medizin. Es geht um verblüffende Durchbrüche, strukturelle Ungerechtigkeiten und offene Fragen - und am Ende um den Knackpunkt: Wie kann das für alle ermöglicht werden? HINTERGRUNDINFORMATIONENAktuelle Zahlen des RKI zur Überlebensrate bei Krebs: https://www.rki.de/DE/Aktuelles/Publikationen/Epidemiologisches-Bulletin/2026/05_26.pdf?__blob=publicationFile&v=4 CAR-T-Zell Therapie am UKE in HH https://www.uke.de/landingpage/zukunftsplan-2050/medizin-der-zukunft/02-lebende-medikamente-car-t-zell-immuntherapie.html Nobelpreis 2018 für Entdeckung der Checkpoint Inhibitoren https://www.aerzteblatt.de/archiv/nobelpreis-fuer-medizin-lahme-abwehr-scharf-machen-4650bfd8-f683-48df-aa52-3543bf18ae09 Übersicht über Immuntherapien vom Deutschen Krebsforschungszentrum (DKFZ) in Heidelberg: https://www.krebsinformationsdienst.de/immuntherapie Übersicht über Biontech-Studien zur mRNA-Impfung gegen Krebs: https://investors.biontech.de/de/news-releases/news-release-details/biontech-praesentiert-auf-der-44-jp-morgan-healthcare-konferenz UKE-Beteiligung an Zulassungsstudie zur Impfung gegen Hautkrebs: https://www.uke.de/landingpage/zukunftsplan-2050/medizin-der-zukunft/32-die-spritze-gegen-den-killer.html Ergebnisse der Phase 2-Studie zur Impfung gegen Hautkrebs: https://pubmed.ncbi.nlm.nih.gov/38246194/ Personalisierte Medizin - Der Fall Mila: https://www.doccheck.com/de/detail/articles/23611-mila-die-auserwaehlte Deutsches Krebsforschungszentrum (DKFZ) - Berechnung der Kosten einer typischen Medikamentenentwicklung: https://www.dkfz.de/aktuelles/pressemitteilungen/detail/was-kostet-die-entwicklung-eines-arzneimittels-wirklich Hörtipp: Podcast “Die Ernährungsdocs”: https://www.ardaudiothek.de/sendung/die-ernaehrungs-docs-essen-als-medizin/urn:ard:show:c9684369f9824d59/Habt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.de.Hier geht's zur Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHier geht's zu ARD Gesund:https://www.ndr.de/ratgeber/gesundheit

Wenn keine Chemotherapie mehr anschlägt, hilft manchmal eine individuelle Gentherapie. Wie funktioniert das - und für wen?Zwölf Mal hat der Krebspatient Torben Lorenz Chemotherapie bekommen, doch der Tumor wuchs weiter. Dann brachte eine CAR-T-Zell-Therapie die Wende – ein innovatives Verfahren, bei dem Immunzellen des Patienten gentechnisch zur spezialisierten Eingreiftruppe umprogrammiert werden.Die Personalisierte Medizin gilt als Gamechanger in der Onkologie und in weiteren Bereichen der Medizin. Unsere Autorin Daniela Remus hat Torben Lorenz in Heide besucht und Genforscher, Neurologen und Onkologen zu den Perspektiven von CAR-T-Zellen, Checkpoint-Inhibitoren und therapeutischer mRNA-Impfung befragt. Im Gespräch mit Host Korinna Hennig erklärt sie, wie man Krebszellen daran hindern kann, das Immunsystem auszutricksen. Sie berichtet über große Chancen, aber auch ökonomische Grenzen der Personalisierten Medizin. Es geht um verblüffende Durchbrüche, strukturelle Ungerechtigkeiten und offene Fragen - und am Ende um den Knackpunkt: Wie kann das für alle ermöglicht werden? HINTERGRUNDINFORMATIONENAktuelle Zahlen des RKI zur Überlebensrate bei Krebs: https://www.rki.de/DE/Aktuelles/Publikationen/Epidemiologisches-Bulletin/2026/05_26.pdf?__blob=publicationFile&v=4 CAR-T-Zell Therapie am UKE in HH https://www.uke.de/landingpage/zukunftsplan-2050/medizin-der-zukunft/02-lebende-medikamente-car-t-zell-immuntherapie.html Nobelpreis 2018 für Entdeckung der Checkpoint Inhibitoren https://www.aerzteblatt.de/archiv/nobelpreis-fuer-medizin-lahme-abwehr-scharf-machen-4650bfd8-f683-48df-aa52-3543bf18ae09 Übersicht über Immuntherapien vom Deutschen Krebsforschungszentrum (DKFZ) in Heidelberg: https://www.krebsinformationsdienst.de/immuntherapie Übersicht über Biontech-Studien zur mRNA-Impfung gegen Krebs: https://investors.biontech.de/de/news-releases/news-release-details/biontech-praesentiert-auf-der-44-jp-morgan-healthcare-konferenz UKE-Beteiligung an Zulassungsstudie zur Impfung gegen Hautkrebs: https://www.uke.de/landingpage/zukunftsplan-2050/medizin-der-zukunft/32-die-spritze-gegen-den-killer.html Ergebnisse der Phase 2-Studie zur Impfung gegen Hautkrebs: https://pubmed.ncbi.nlm.nih.gov/38246194/ Personalisierte Medizin - Der Fall Mila: https://www.doccheck.com/de/detail/articles/23611-mila-die-auserwaehlte Deutsches Krebsforschungszentrum (DKFZ) - Berechnung der Kosten einer typischen Medikamentenentwicklung: https://www.dkfz.de/aktuelles/pressemitteilungen/detail/was-kostet-die-entwicklung-eines-arzneimittels-wirklich Hörtipp: Podcast “Die Ernährungsdocs”: https://www.ardaudiothek.de/sendung/die-ernaehrungs-docs-essen-als-medizin/urn:ard:show:c9684369f9824d59/Habt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.de.Hier geht's zur Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHier geht's zu ARD Gesund:https://www.ndr.de/ratgeber/gesundheit

Send us a textGeorge Jerjian, had a life altering diagnosis in 2007 at the age of 52, a tumor that was meant to be life ending. All the odds were stacked against him, yet he survived to tell the tale! The experience changed the way he thought, and perceived life, and more specifically, as he approached retirement, he wanted to make sure his life continued with purpose. George is now a Retirement Mindset Mentor, and brings his real-world experience helping people aged 55–75 reframe aging and rediscover identity beyond job titles. Its a brilliant episode and highly relatable to literally anyone in any stage of life. Site: https://georgejerjian.com/Support the show

Osteosarcoma Webinar Series: David Ulmert, MD, PhD, an Associate Professor at UCLA, discusses his OutSmarting Osteosarcoma funded work (Because of Sydney) on high-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches.Dr. Ulmert will discuss his lab's work investigating how osteosarcoma responds to LRRC15-targeted radiotherapy, with patient translation anticipated this year. Using high-throughput technologies, the team will identify biomarkers, predictive models, and key transcriptional regulators driving the TGFβ–LRRC15 axis. He will review how radiopathobiological changes and immune reprogramming are being mapped to uncover druggable events and inform co-treatment strategies, accelerating near-term impact on patient studies and next-generation therapeutic development.Dr. David Ulmert is an expert in oncology and biotechnology, specializing in cancer biomarkers and targeted therapies. His research focuses on antigens secreted by luminal tissues as novel cancer-specific targets and circulating biomarkers. He developed high-affinity antibodies against androgen receptor-regulated enzymes hK2 and PSA, now in clinical trials across the US, Europe, and Australia—in collaboration with Janssen—for radioimmunotheranostics, CAR-T therapy, and bispecific targeting. His lab also developed DUNP19, an LRRC15-targeting antibody licensed to Lantheus, with a Phase 1 trial in osteosarcoma planned for 2025. Dr. Ulmert leads UCLA's Preclinical Theranostics Program and conducts population-based studies on cancer biomarkers and risk factors with international collaborators. He is widely recognized for advancing prostate cancer research and translational immunotheranostics.

  ⏰

What if the most powerful cancer treatments already exist — but aren't being offered because they fall outside the guidelines?In this episode of Integrative Cancer Solutions, Dr. Michael Karlfeldt sits down with world-renowned interventional radiologist and oncology innovator Dr. Syed Hasnain Haider-Shah to explore why modern cancer care often prioritizes protocols over patients. From catheter-directed chemotherapy and tumor embolization to immune-based strategies, photobiomodulation, and precision nutrition, Dr. Shah reveals how advanced cancer treatments are being used globally — especially in China — while remaining largely inaccessible in the U.S.This conversation dives deep into the limitations of chemotherapy and radiation, the intelligence of cancer stem cells, immune system suppression, cancer cachexia, and why integrative, individualized approaches give patients their best chance at long-term survival. If you or someone you love is navigating a cancer diagnosis and searching for real options beyond “standard of care,” this episode is essential listening.Key Takeaways:5:20 Radiation therapy risks and how to support recovery nutritionally11:46 Why systemic chemotherapy often fails and selects for aggressive cancer cells12:17 Catheter-directed chemotherapy: targeting tumors without poisoning the body16:25 The immune system as the most powerful anti-cancer weapon26:37 Tumor embolization: starving cancer by cutting off its blood supply34:50 Why advanced cancer therapies thrive in China but are restricted in the U.S.Resources Mentioned:Williams Cancer Institute (Mexico) – https://williamscancerinstitute.comPhotobiomodulation / Intravenous Light Therapy (General Overview) – https://pubmed.ncbi.nlm.nih.gov Want to guest on our shows?Calendly Link for Integrative Lyme Solutions: https://calendly.com/drmichaelk/integrative-lyme-solutions-podcast-interviewCalendly Link for Integrative Cancer Solutions: https://calendly.com/drmichaelk/podcast-interviewCalendly Link for Dr. K Show: https://calendly.com/drmichaelk/dr-k-show-interview Breaking Free From Lyme: A Comprehensive Guide to Healing and Recovery-URL: https://store.thekarlfeldtcenter.com/products/breaking-free-from-lyme-Price: $24.99-Discount Code: LYMEPODCASTUnleashing 10X Power: A Revolutionary Approach to Conquering Cancer-URL: https://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancer-URL: https://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-Discount Code: CANCERPODCAST2The Science and Spirit of Transformation: A Holistic Guide to Elevating Health, Consciousness, and Purpose-URL: https://store.thekarlfeldtcenter.com/products/the-science-and-spirit-of-transformation-Price: $24.99-Discount Code: DRKSHOWPODCAST -----------------------------------------------A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health ThreatGrab my book here: https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering CancerGet it here: https://store.thekarlfeldtcenter.com/products/unleashing-10x-powerPrice: $24.99100% Off Discount Code: CANCERPODCAST1 Healing Within: Unraveling the Emotional Roots of CancerGet it here: https://store.thekarlfeldtcenter.com/products/healing-withinPrice: $24.99100% Off Discount Code: CANCERPODCAST2-----------------------------------------------Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Steve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care.  The platform also helps patients find relevant clinical trials and manage the side effects of their treatments. Steve explains, "So the mission really is to harness AI to advance cancer care. And ultimately, for that reason, anybody who's touched by cancer is hopeful that we will be making more progress toward cures for cancer. And we believe that that's going to happen through precision medicine, which really means recognition that everybody's cancer is unique. And at some point, we're going to treat cancer that way because we're going to know enough about how it all works. We're going to be able to individualize care. So our mission is to advance that cause."   Lisa elaborates, "When Steve and I started working together, one of the things I said was that I needed a way as a patient to be able to access different perspectives of a radiologist, an interventional radiologist, a pathologist, a geneticist, an oncologist, etc. And I can get that in Seattle, but most of the people I work with can't, meaning the patients and my friends in the cancer community don't have access to that because they don't exist in their communities."   #CancerCare #AI #PrecisionMedicine #PatientEmpowerment #HealthTech #CancerSurvivors #DigitalHealth #Oncology #TumorBoard #ClinicalTrials #HealthcareInnovation #PatientAdvocacy #PatientLedInnovation #CancerAndAI #TumorBoardTech #AIForPatients #SteveBrownAI #LisaBoothSurvivor #MedicalAutonomy #HealthTechWithHeart #NOfOneMedicine curewise.com Listen to the podcast here

Steve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care.  The platform also helps patients find relevant clinical trials and manage the side effects of their treatments. Steve explains, "So the mission really is to harness AI to advance cancer care. And ultimately, for that reason, anybody who's touched by cancer is hopeful that we will be making more progress toward cures for cancer. And we believe that that's going to happen through precision medicine, which really means recognition that everybody's cancer is unique. And at some point, we're going to treat cancer that way because we're going to know enough about how it all works. We're going to be able to individualize care. So our mission is to advance that cause."   Lisa elaborates, "When Steve and I started working together, one of the things I said was that I needed a way as a patient to be able to access different perspectives of a radiologist, an interventional radiologist, a pathologist, a geneticist, an oncologist, etc. And I can get that in Seattle, but most of the people I work with can't, meaning the patients and my friends in the cancer community don't have access to that because they don't exist in their communities."   #CancerCare #AI #PrecisionMedicine #PatientEmpowerment #HealthTech #CancerSurvivors #DigitalHealth #Oncology #TumorBoard #ClinicalTrials #HealthcareInnovation #PatientAdvocacy #PatientLedInnovation #CancerAndAI #TumorBoardTech #AIForPatients #SteveBrownAI #LisaBoothSurvivor #MedicalAutonomy #HealthTechWithHeart #NOfOneMedicine curewise.com Download the transcript here

Die Zahlen sind eindrücklich: Mehr als jede dritte Frau und jeder zweite Mann in der Schweiz sind im Lauf ihres Lebens von einer Krebserkrankung betroffen. Klingt nach viel. Gleichzeitig heisst es: Weltweit könnten vier von zehn Krebs-Erkrankungen verhindert werden. Wir ordnen das ein. Wie steht es um Prävention, Behandlung und Krebsforschung? So viel vorweg: In einigen Bereichen ist die Schweiz Spitze, in anderen hat sie enorm aufzuholen. Der Spezialist erklärt das und sagt auch, weshalb es wichtig ist zu verstehen, dass unser Körper funktioniert wie ein Kopiergerät. ____________________ Habt Ihr Fragen oder Themen-Inputs? Schreibt uns gerne per Mail an newsplus@srf.ch oder sendet uns eine Sprachnachricht an 076 320 10 37. ____________________ In dieser Episode zu hören: - Anna Baptista, Pflegeassistentin und Begleiterin von Betroffenen bei der Krebsliga - Roger von Moos, Direktor des Tumor- und Forschungszentrums im Kantonsspital Graubünden ____________________ Link: - SRF-Sendung "Puls": https://www.srf.ch/play/tv/puls/video/diagnose-krebs---was-nun?urn=urn:srf:video:69107237-c2cd-4495-b32d-0def4e53f399 ____________________ Team: - Moderation: Susanne Stöckl - Produktion: Marisa Eggli - Mitarbeit: Gabriel Gasser ____________________ Das ist «News Plus»: In einer Viertelstunde die Welt besser verstehen – ein Thema, neue Perspektiven und Antworten auf eure Fragen. Unsere Korrespondenten und Expertinnen aus der Schweiz und der Welt erklären, analysieren und erzählen, was sie bewegt. «News Plus» von SRF erscheint immer von Montag bis Freitag um 16 Uhr rechtzeitig zum Feierabend.

You're about to biopsy a renal lesion; should you ablate at the same time? In this episode of the BackTable Podcast, host Michael Barraza talks with Dr. Steven Huang from MD Anderson Cancer Center about building an efficient and effective renal biopsy and ablation service line. --- This podcast is supported by: Varian IntelliBlatehttps://www.varian.com/products/interventional-solutions/microwave-ablation-solutions --- SYNPOSIS Dr. Huang first covers referral patterns and the typical pathway that patients take to end up in his clinic. The discussion covers the types of lesions he treats, imaging requirements, and criteria for patient eligibility. He emphasizes the importance of shared decision making when deciding between active surveillance, interventional treatment, and partial nephrectomy. Dr. Huang explains his preferred procedural approach and ablation modalities, including cryo, microwave (MWA), and radiofrequency ablation (RFA). He shares his experiences with challenging cases and integrating new technologies like histotripsy and the Siemens interventional package. They also discuss the possibility of a preoperative embolization for larger lesions that could be susceptible to the heat sink effect. Both experts emphasize the importance of collaboration with urologists and ensuring patient safety and expectations. They also touch on the future of the field, discussing the use of AI and robotics. --- TIMESTAMPS 00:00 - Introduction 02:17 - Training Programs at MD Anderson03:23 - Referral Patterns for Renal Ablations07:25 - Patient Management and Virtual Consultations10:59 - Ablation Techniques and Device Selection26:44 - Challenges and Complications27:25 - Approach to Lesions Near Renal Vasculature28:02 - Patient Expectations and Urologist Collaboration33:26 - Post-Procedure Care and Patient Recovery35:30 - Managing Recurrences and Multiple RCCs47:17 - Closing Remarks

Einer der größten Killer der Menschheitsgeschichte könnte besiegt werden. Neue Krebsimpfstoffe könnten innerhalb eines Jahrzehnts Realität werden. In der Forschung vorn dabei ist das Mainzer Unternehmen Biontech. Den „Tagesanbruch" gibt es auch zum Nachlesen unter [t-online.de/tagesanbruch](https://www.t-online.de/tagesanbruch) Anmerkungen, Lob und Kritik gern an podcasts@t-online.de Den „Tagesanbruch“-Podcast gibt es immer montags bis freitags ab 6 Uhr zum Start in den Tag vorgelesen von einer freundlichen KI-Stimme – am Wochenende mit einer tiefgründigeren Diskussion. Verpassen Sie keine Folge und abonnieren Sie uns bei [Spotify] https://open.spotify.com/show/3v1HFmv3V3Zvp1R4BT3jlO?si=klrETGehSj2OZQ_dmB5Q9g), [Apple Podcasts](https://itunes.apple.com/de/podcast/t-online-tagesanbruch/id1374882499?mt=2), [Amazon Music](https://music.amazon.de/podcasts/961bad79-b3ba-4a93-9071-42e0d3cdd87f/tagesanbruch-von-t-online) oder überall sonst, wo es Podcasts gibt. Wenn Ihnen der Podcast gefällt, lassen Sie gern eine Bewertung da.

As part of IASLC's ongoing series of Lung Cancer Considered podcast episodes in world languages, Dr. Ece Cali moderates a discussion in Turkish with Dr. Irfan Çiçin and Dr. Fulden Yumuk. The episode is part of our Virtual Tumor Board series and focuses on immunotherapy for non-small cell lung cancer (NSCLC).

In this JCO Precision Oncology Article Insights episode, host Dr. Jiasen He summaries the article, "Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors," by Hassoun et al. TRANSCRIPT Jiasen He: Hello, and welcome to the JCO Precision Oncology Article Insights. I'm your host, Jiasen He, and today, we'll be discussing the JCO Precision Oncology article, "Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors," by Dr. Rebecca Hassoun and colleagues. Traditionally, treatment response for solid tumors has relied on imaging, which focuses on visible anatomic changes in the tumor. However, imaging does not always reflect molecular or cellular changes and cannot detect microscopic disease, which is clinically important and often linked to relapse. Liquid biopsy, on the other hand, is minimally invasive and can be used for cancer monitoring by analyzing circulating biomarkers in biofluids such as blood. One type of liquid biopsy is circulating tumor DNA, or ctDNA, which measures small fragments of DNA released by tumor cells into the bloodstream. ctDNA can allow precise monitoring of tumor-specific mutations and be a powerful tool for assessing treatment responses. ctDNA has already been applied in clinical settings for cancers such as non-small cell lung cancer and breast cancer, etcetera. However, there is still limited data on the use of ctDNA for germ cell tumors. Germ cell tumors are the most common malignancy affecting men aged 15 to 35 years. Accurate risk stratification and disease monitoring is key to risk-adapted therapy, maximizing the chance of cure while minimizing side effects. One unique tool we use currently for diagnosis, staging, and monitoring is serum tumor markers, such as AFP, beta-hCG, and LDH. However, these markers have limitations, including false elevation in certain clinical scenarios, and studies have shown that they can be normal in up to 40 percent of patients with germ cell tumor. This creates an unmet need for other sensitive and specific biomarkers to improve patient care. In this paper, the authors investigated the use of ctDNA in a cohort of patients with germ cell tumor at various disease time points. They compared ctDNA results with traditional serum tumor markers to evaluate whether ctDNA can predict relapse and survival outcomes. This multi-institutional retrospective study included patients with stage I, II, and III germ cell tumors, primarily testicular cancer, who had at least one ctDNA test result. ctDNA was evaluated longitudinally at different time points, including pre-orchiectomy, during the molecular residual disease, or MRD, window, defined as 1 to 12 weeks post-orchiectomy but before primary therapy, and during the surveillance window, defined as more than 12 weeks post-orchiectomy or follow retroperitoneal lymph node dissection or post-chemotherapy. ctDNA analysis was performed using a tumor-informed 16 multiplex PCR next-generation sequencing assay. A total of 324 plasma samples were analyzed from 74 patients in this cohort. The majority had stage I disease, around 40 percent, and nonseminomatous histology, around 70 percent. 15 patients were evaluated in the pre-orchiectomy window, and only one patient tested negative for ctDNA. This patient had stage I disease. The authors further assessed ctDNA positivity in both the MRD window and surveillance window, evaluating its association with event-free survival. They found that ctDNA outperformed serum tumor markers in both settings. ctDNA positivity was associated with significantly worse event-free survival compared with ctDNA-negative patients. Among the 14 patients with stage II to III disease who had ctDNA assessed in both the MRD window and surveillance window, nine patients consistently had a negative ctDNA or converted from positive to negative over time. In contrast, five patients demonstrated persistent ctDNA positivity, and all of these patients subsequently relapsed. Among the 38 patients who had both ctDNA and serum tumor marker tests during the MRD window, nine patients showed discordant biomarker results. Of these, 6 patients were ctDNA-negative but serum tumor marker-positive, and one of them experienced recurrence. Three patients were ctDNA-positive but serum tumor marker-negative, and one of these patients also recurred. During the surveillance window, 46 patients had both biomarkers available, and 10 showed discordant results. Three patients were ctDNA-negative but serum tumor marker-positive, and none of them recurred. In contrast, all seven patients who were ctDNA-positive but serum tumor marker-negative experienced recurrence. This intriguing data strongly support the potential role of ctDNA in patients with stage I, II, and III germ cell tumors. However, as the authors noted, the retrospective nature of the study presents limitations, as treatment approaches, imaging schedules, and the timing of testing were not standardized, and ctDNA testing varies among participating institutions. Larger prospective trials with standardized protocols and long-term follow-up will be essential to validate these findings and determine how ctDNA can be reliably integrated into clinical practice. Thank you for tuning in to JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Nova temporada do Pipoca TdC no ar!

In today's Beating Cancer Daily episode, Saranne explores creating a living legacy with excitement and optimism. As someone who has beaten Stage IV cancer for 30 years, Saranne shares her perspective on why it's essential to consciously think about and enjoy crafting a legacy, regardless of the timeline we have. Join her as she discusses fun and creative ways to leave a lasting imprint, from recording books for loved ones to planting living markers of our time. Get ready to be inspired and discover how embracing the concept of legacy can bring joy and depth to our lives as we beat cancer daily together.2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 140 countries across 7 continents and features over 400 original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne  

Send a textYour heart sinks when a dog's CT shows a primary liver tumor plus extra lesions. Ours used to as well—until we dug into data showing how often those additional masses are actually benign. In this conversation with surgical oncologists Drs. Samuel Burkhardt and Hunter Piegols, we rethink what “multiple hepatic lesions” really means, and how that shift can change everything from pre-op counseling to what you sample in the OR.We walk through their study design—primary liver tumors paired with additional lesions verified by surgical exploration and histopathology—and why imaging alone couldn't separate benign from malignant with confidence. You'll hear practical guidance on interpreting CT findings without leaping to metastasis, framing owner conversations to avoid a falsely negative outlook, and planning targeted biopsies that refine staging and inform follow-up. We also tackle the language problem: nodule versus mass. Without common definitions, clinicians and researchers risk misreading severity and muddying the literature. The case for cross-disciplinary standards and working groups is compelling.Looking ahead, we explore tools that could improve preoperative decisions: contrast-enhanced ultrasound, more rigorous imaging criteria adapted from human medicine, and the promise of liquid biopsy and biomarkers to flag “bad actor” hepatocellular carcinomas. We discuss sample-size limits in veterinary studies, the value of multi-institutional collaboration, and related puzzles like what a solitary pulmonary nodule really means for prognosis. Along the way, you'll pick up succinct surgical maxims, practical tips for histopath submission, and a reminder that small resets outside the clinic help us think clearly when cases get complex.If this conversation helps you reframe your next liver case, share it with a colleague, subscribe for more evidence-based episodes, and leave a review so others can find the show.JAVMA article: https://doi.org/10.2460/javma.25.07.0514INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Send us a textWe're going back Down Under for a really impressive comeback story. Olli Bryers was what we Americans would stereotype as a young, carefree, adventurous Australian who liked to surf, backpack, travel, and occasionally party. Usually, that youthful bliss only gets interrupted when the real world says that maybe you need to find a job to finance this lifestyle, or get serious about a long-term career path. But in Olli's case, that jolt came in his early 20s from the discovery of a spinal tumor that necessitated a surgery that could rob his ability to ever walk again. Fortunately, the doctors were successful in removing the tumor and it was benign. Improbably, just six months later, Olli toed the starting line of his very first triathlon, in his hometown of Newcastle in the state of New South Wales. But that wasn't the end of this amazing comeback story because Olli never would have completed the race without the generosity of another competitor. His finish time was 1:27:16, placing him 114th out of 304 who completed it. But I have a feeling that this is only the beginning for this young Aussie, who as you'll hear in this interesting chat has a lot of gratitude and a very mature attitude about the meaning of his surviving this ordeal intact, including how to approach life and being kinder to those around you. Plus, I've got to say that Olli told me I'm “cruisy,” which I took as a compliment. You'll have to look that one up in your Aussie slang dictionary.Olli BryersInstagram @olli.bryersBill Stahlsilly_billy@msn.comFacebook Bill StahlInstagram and Threads @stahlor and @we_are_superman_podcastYouTube We Are Superman PodcastSubscribe to the We Are Superman Newsletter!https://mailchi.mp/dab62cfc01f8/newsletter-signupSubscribe to our Substack for my archive of articles of coaching tips developed from my more than three decades of experience, wild and funny stories from my long coaching career, the wit and wisdom of David, and highlights of some of the best WASP episodes from the past that I feel are worthwhile giving another listen.Search either We Are Superman Podcast or @billstahl8Register for the American Heroes Run: https://ultrasignup.com/register.aspx?did=133138

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Benign Bone Tumors⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

What a day. Believe it or not, these are feel good stories. Join me. — Support and sponsor this show! Venmo Tip Jar: @wellthatsinteresting Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wellthatsinterestingpod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Bluesky: @wtipod Threads: @wellthatsinterestingpod Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wti_pod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Listen on YouTube!! Oh, BTW. You're interesting. Email YOUR facts, stories, experiences... Nothing is too big or too small. I'll read it on the show: wellthatsinterestingpod@gmail.com WTI is a part of the Airwave Media podcast network! Visit AirwaveMedia.com to listen and subscribe to other incredible shows. Want to advertise your glorious product on WTI? Email me: wellthatsinterestingpod@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

February 2026 Journal Club Podcast Title: Maximizing Tumor Resection and Managing Cognitive Attentional Outcomes: Measures of Impact of Awake Surgery in Glioma Treatment To read journal article: https://journals.lww.com/neurosurgery/fulltext/2026/02000/maximizing_tumor_resection_and_managing_cognitive.15.aspx Authors: Silvio Sarubbo and Luca Zigiotto Guest Faculty: Pablo Valdes Resident Planner: Alexander Himstead Podcast Committee Vice Chair/Moderator: Martin Pham

Annika ist 26, als bei ihr ein Borderline-Tumor entdeckt wird. Das Tückische an dieser Diagnose: Die Zysten an ihren Eierstöcken sind gleichzeitig gut- und bösartig. Für die Studentin beginnt ein emotionales Auf und Ab zwischen Entwarnungen und immer wieder neuen schlechten Neuigkeiten. Doch mit den Herausforderungen wird die junge Frau zunehmend Expertin für ihren eigenen Körper und will jetzt anderen Halt geben.

Getting a cancer diagnosis today can mean something very different than it meant a few decades ago.  Cancer is still deadly. But thanks to advances in detection and treatment, cancer for some people has turned into a manageable condition. A report from the American Cancer Society out this week shows that for the first time that the five-year survival rate for all cancers has reached 70 percent. Tumors are being found at earlier stages, when treatment can be more effective. Surgery and radiation have gotten more precise.  Researchers have refined their understanding of different types of cancers and developed new drugs that zero in on the unique biology of specific tumors.Maybe most importantly, researchers are figuring out how to use the body's own immune system to fight cancer in ways that doctors couldn't have imagined 20 years ago.  MPR News host Angela Davis talks with her guests about how cancer treatments are improving.Guests: Dr. Emil Lou is a medical oncologist and professor at the University of Minnesota Medical School who sees patients at M Health Fairview Masonic Cancer Clinic. He specializes in gastrointestinal cancers, such as colorectal and pancreas cancers, and is also involved in cancer research.  Dr. Rachel L McCaffrey is a breast surgical oncologist at Allina Health who specializes in treating breast cancer. 

Featuring an interview with Dr Scott Kopetz, including the following topics:  Circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy de-escalation in the treatment of Stage III colon cancer from the ctDNA-negative cohort of the DYNAMIC-III trial (0:00) Prognostic and predictive role of ctDNA in the management of Stage III colon cancer treated with celecoxib: Findings from the CALGB (Alliance)/SWOG 80702 trial (8:01) Phase III ALTAIR study comparing trifluridine/tipiracil to placebo for patients with molecular residual disease after curative resection of colorectal cancer (CRC); a methylation-based, tissue-free ctDNA test (12:51) ctDNA with locally advanced mismatch repair-deficient/microsatellite instability-high solid tumors; real-world evidence regarding ctDNA with resected CRC (17:31) CME information and select publications

In today's episode, Saranne delves into the world of tumor humor as she reflects on her experience with hair loss during her cancer journey. As a survivor, Saranne understands the emotional impact of losing hair during cancer treatment and shares how she approached this challenging experience with a comic perspective. Join her as she discusses the humorous side of coping with hair loss and invites listeners to participate in creating their tumor humor. Prepare for a lighthearted and insightful discussion on finding laughter in the face of adversity as we beat cancer daily together.2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 140 countries across 7 continents and features over 400 original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne  

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer. CME information and select publications here.

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer. CME information and select publications here.

Osteosarcoma Webinar Series: Izuchukwu Ibe, MD, a musculoskeletal oncologist, Associate Professor, and Residency Program Director at the University of Mississippi Medical Center joins us on OsteoBites to discuss insights and highlights from the Musculoskeletal Tumor Society (MSTS) December 2025 Annual Meeting, December 3-5 in Mexico City.Dr. Ibe is a Musculoskeletal Oncologist with a residency from Yale and a Fellowship from the University of Toronto. He is passionate about educating patients and families with a sarcoma diagnosis and channels this through his Sarcoma Insights podcasts. He enjoys soccer and spending time with his family.

In this JCO Precision Oncology Article Insights episode, host Dr. Harold Nathan Tan summarizes "Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study" by Worden et al.  TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights, where we explore research that is reshaping our understanding of cancer therapeutics. I'm your host, Harold Nathan Tan, and today's episode centers on the TAPUR study, an analysis that confronts a long-standing assumption in molecular oncology: namely, whether CDKN2A alterations create a therapeutic vulnerability that can be exploited by CDK4/6 inhibition with palbociclib. CDKN2A is one of the most frequently altered tumor suppressors across solid tumors. Its importance lies in its production of two proteins, p16 and p14, which serve as guardians of cell cycle progression. p16 directly inhibits CDK4 and CDK6, preventing phosphorylation of the RB protein and therefore blocking entry into S phase, whereas p14 stabilizes p53 by counteracting MDM2, enabling cells to pause or die in response to oncogenic stress. When CDKN2A is lost or mutated, these dual checkpoints collapse. CDK4/6 activity becomes unchecked, RB remains phosphorylated and inactive, and p53-mediated surveillance is blunted from a mechanistic standpoint. This creates a possible dependency on CDK4/6 signaling that could, in principle, be therapeutically reversed by palbociclib. The TAPUR study is a prospective phase 2 basket study designed to evaluate whether FDA-approved targeted agents can meaningfully benefit patients with advanced treatment-refractory cancers harboring specific genomic alterations. In this analysis, patients were eligible for palbociclib if their tumors carried CDKN2A loss or mutation and retained RB activity. Two cohorts were examined: one consisting of head and neck cancers, and another composed of a broad spectrum of tumor types that collectively shared the CDK2 alteration. The results from the head and neck cancer cohort are particularly intriguing. Among the 28 available patients, the study observed a disease control rate of 40%, surpassing the predefined threshold for a positive signal. Although the objective response rate was low at only 4% with one partial response, the durability of disease stabilization was clinically meaningful. However, the most important insight comes from examining which head and neck tumors benefited. The strongest and most durable disease control occurred in non-squamous malignancies, particularly salivary gland tumors such as adenocarcinoma, adenoid cystic carcinoma, and poorly differentiated parotid tumors, as well as in esthesioneuroblastoma. In contrast, classic head and neck squamous cell carcinoma rarely demonstrated sustained benefit. When progression-free survival was analyzed, non-squamous tumors achieved a median PFS of approximately 20 weeks compared to just eight weeks in squamous tumors. This divergence reflects deep biological differences. Many non-squamous head and neck cancers preserve an intact RB axis and rely on CDK4/6-driven cell cycle control as a core proliferative mechanism. By contrast, squamous tumors tend to accumulate a dense array of co-alterations that weaken or circumvent CDK4/6 dependency. Many squamous tumors also harbor disruptive TP53 mutations, removing essential checkpoint control and allowing the cell to bypass the growth-arresting effects of palbociclib. In other words, even though CDKN2A loss is present, CDK4/6 is no longer the dominant node controlling proliferation in these cancers, and the tumor simply finds other ways to drive cell cycle entry. One of the most thought-provoking findings from the TAPUR study involves esthesioneuroblastoma. Three patients with this rare tumor achieved durable disease control despite the lack of standardized systemic treatment options for this malignancy. Genomic analyses have shown that while esthesioneuroblastoma often carries TP53 or IDH2 mutations, a meaningful subset exhibits alterations in CDKN2A or related cell cycle regulators. The consistency of this disease stabilization observed in TAPUR may reflect a lineage-specific reliance on CDK4/6 signaling, opening the door for future exploration of CDK4/6 inhibitors in this orphan disease. In the histology-pooled cohort, which included 40 available patients across 18 tumor types, palbociclib did not achieve the disease control threshold required to declare activity, with only a disease control rate of 13% and an ORR of 5%. While a few isolated responses occurred, for instance in thymic carcinoma and B-cell lymphoma, the overall disease control rate was 13%, which failed to rise above what might be expected from the natural history of advanced refractory cancers. This outcome reinforces the principle that CDKN2A loss is not a universal predictor of CDK4/6 dependency. Many of the tumors represented in this cohort, such as pancreatic cancer, melanoma, and gastrointestinal malignancies, are well known to evolve multiple compensatory mechanisms that circumvent CDK4/6 as a critical proliferative node. The safety profile of palbociclib was consistent with its known hematologic toxicities. High rates of neutropenia, leukopenia, and thrombocytopenia were observed, along with one treatment-related death due to respiratory failure. In a setting where activity is limited to specific subgroups, these toxicities underscore the importance of careful patient selection and raise the bar for demonstrating clinically meaningful benefit, particularly in heavily pretreated populations. So what do these findings tell us about the broader landscape of precision oncology? First, they remind us that a mutation's functional role is dependent on the cellular and lineage context in which it occurs. CDKN2A loss may accelerate proliferation in many tumors, but the mechanism of that acceleration varies widely, and the degree to which a tumor relies on CDK4/6 signaling is anything but uniform. Second, the findings suggest that palbociclib monotherapy may hold meaningful and durable benefit in the subset of non-squamous head and neck cancers, particularly salivary gland malignancies and esthesioneuroblastoma. Third and perhaps most importantly, the results reinforce a growing consensus that the future of CDK4/6 inhibition in solid tumors lies not in monotherapy, but in rational combination strategies. CDK4/6 inhibitors have been shown to synergize with EGFR inhibitors, PIK3CA, and mTOR inhibitors, MEK inhibition, and even immune checkpoint blockade. These combinations aim to dismantle the compensatory pathways that allow tumors to escape CDK4/6 blockade and may unlock therapeutic potential in tumors that show limited sensitivity to monotherapy. Ultimately, the TAPUR findings challenge the notion that CDKN2A is a straightforward predictive biomarker. Instead, the study reveals CDKN2A as a biomarker whose meaning is modulated by tumor lineage, co-mutation status, and the broader regulatory circuit governing proliferation. Precision oncology must therefore move beyond single-gene interpretation towards integrated frameworks that situate genomic alterations within their biologic ecosystems. In some head and neck cancer subtypes, particularly non-squamous malignancies, that ecosystem appears amenable to CDK4/6 inhibition, and that insight, not the simplistic gene-to-drug match, represents the true value of the TAPUR analysis. Thank you for joining me for this episode of JCO Precision Oncology Article Insights. I'm Harold Nathan Tan, and I look forward to exploring more research that continues to refine how we understand and strategically exploit the vulnerabilities of cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Featuring an interview with Dr Scott Kopetz, including the following topics: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) and survival among patients with resectable colorectal cancer (CRC) in the CIRCULATE-Japan GALAXY trial (0:00) ctDNA for detection of MRD in patients with CRC in the BESPOKE CRC and INTERCEPT trials (3:11) Clinical utility of including ctDNA monitoring in standard CRC surveillance (11:11) ctDNA analysis guiding adjuvant therapy for CRC in the DYNAMIC and CIRCULATE-North America trials (15:52) CME information and select publications

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer.CME information and select publications here.

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer.CME information and select publications here.

In today's episode, Saranne, the founder of the Comedy Cures Foundation, shares her unique perspective on humor and cancer treatment. She introduces the "Tumor Humor" concept and how she developed her comic perspective while undergoing cancer treatment. Saranne shares a humorous joke about her blood test results and explains the inspiration behind it. She encourages listeners to find the comedic elements in their own cancer journey and invites them to share their jokes or stories with the Comedy Cures Foundation. Join Saranne as she explores the intersection of laughter and healing in the face of cancer.2025 People's Choice Podcast Awards FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024Beating Cancer Daily is listened to in over 130 countries across 7 continents and features over 390 original daily episodes hosted by Stage IV survivor Saranne Rothberg.  To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_SuggestionsTo sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review.Have a blessed day! Saranne

In cancer research, the “seed and soil” hypothesis posits that the tumor is like a seed of misbehaving cells taking root in the body. Whether it grows—and where it grows—depends on the conditions, or soil. Since this hypothesis was proposed more than 100 years ago, most research and treatments have focused on the seed, or tumor. For nearly 50 years, Rakesh Jain has been studying the soil. But in a seed-focused field, his work was seen as wasteful and radical. Now, that very same research has led to seven FDA-approved treatments for diseases including lung and liver cancer, and earned him a National Medal of Science in 2016. Host Flora Lichtman talks with Jain about how his fringe idea led to lifesaving cancer treatments. Guest: Dr. Rakesh K. Jain studies the biology of tumors at Harvard Medical School and Massachusetts General Hospital as a professor of radiation oncology.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Marty Makary explains how the FDA began after toxic chemicals in food caused deaths, how it grew to regulate 20 percent of the US economy, and what he has changed in his first eight months including removing artificial dyes, cutting red tape, adding AI, and rewriting the food pyramid.